# Sotalol

Drug · id `cardio:sotalol` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Betapace; Betapace AF

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

Sotalol, sold as Betapace and Betapace AF, is a medicine taken by mouth that the US label describes as an antiarrhythmic, a medicine for heart rhythm problems, with both beta-blocking properties and properties that lengthen the heart's action potential. The label read, one label for the two brands, lists two uses: the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia (the label says it has not been shown to enhance survival in these patients); and keeping normal sinus rhythm, by delaying the recurrence of atrial fibrillation or flutter, in people with highly symptomatic episodes who are currently in sinus rhythm. It carries a boxed warning about life-threatening proarrhythmia, a drug-caused worsening of heart rhythm.

## Technical summary

RxNorm ingredient 9947 (sotalol); the label names the salt sotalol hydrochloride (RxNorm 7008, UNII HEC37C70XX, a broad match to the ingredient). MeSH descriptor D013015 is Sotalol. RxClass lists the FDA established pharmacologic class Antiarrhythmic (the page files under that class), a beta-receptor antagonist mechanism class and the physiologic effect Cardiac Rhythm Alteration. The label read is the Legacy Pharma USA, Inc. label for Betapace and Betapace AF, application NDA019865 in openFDA, effective 2024-12-16; Drugs@FDA lists Betapace AF under its own application NDA021151. Sotylize oral solution (NDA205108), Sorine and generic sotalol labels, and sotalol injection labels, were not read. This page records label indications, the class, the mechanism sentence and the title and first sentence of the boxed warning only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Patients taking sotalol, as described in a US Betapace and Betapace AF label boxed warning

Recipient: Recipient not specified; Population: Patients who take the medicine, as the boxed warning describes the risk. The passages read give no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label carries a boxed warning titled life-threatening proarrhythmia. It says the medicine can cause life-threatening ventricular tachycardia associated with QT interval prolongation.

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients who take the medicine, as the boxed warning describes the risk. The passages read give no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records the title and first statement of the label's boxed warning only. The warning goes on to tell prescribers where treatment is started and what to do if the QT interval lengthens; those instructions are not repeated here. Other warnings, contraindications and interactions were not recorded. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for Betapace and Betapace AF (sotalol hydrochloride tablets), Legacy Pharma USA, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id a6a7702f-36c9-45db-b640-453dc324baee (manufacturer Legacy Pharma USA, Inc., application NDA019865; one label for the two brands Betapace and Betapace AF), returned on 2026-11-18. The label text is dated 2024-12-16 (effective\_time). Other openFDA records of sotalol labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22a6a7702f-36c9-45db-b640-453dc324baee%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], title. Retrieved 2026-11-18T21:55:11Z. Source state: Current. Version fingerprint: c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00.
     How it applies: Label passage quoted in the research quote table (LB-10).
  2. Supports: openFDA drug label record for Betapace and Betapace AF (sotalol hydrochloride tablets), Legacy Pharma USA, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id a6a7702f-36c9-45db-b640-453dc324baee (manufacturer Legacy Pharma USA, Inc., application NDA019865; one label for the two brands Betapace and Betapace AF), returned on 2026-11-18. The label text is dated 2024-12-16 (effective\_time). Other openFDA records of sotalol labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22a6a7702f-36c9-45db-b640-453dc324baee%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], first paragraph. Retrieved 2026-11-18T21:55:11Z. Source state: Current. Version fingerprint: c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00.
     How it applies: Label passage quoted in the research quote table (LB-11).
  3. Background: openFDA drug label record for Betapace and Betapace AF (sotalol hydrochloride tablets), Legacy Pharma USA, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id a6a7702f-36c9-45db-b640-453dc324baee (manufacturer Legacy Pharma USA, Inc., application NDA019865; one label for the two brands Betapace and Betapace AF), returned on 2026-11-18. The label text is dated 2024-12-16 (effective\_time). Other openFDA records of sotalol labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22a6a7702f-36c9-45db-b640-453dc324baee%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T21:55:11Z. Source state: Current. Version fingerprint: c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00.
     How it applies: Effective date of the label text read, 20241216.

## Context: Patients with life-threatening ventricular arrhythmias, or with highly symptomatic atrial fibrillation or flutter who are in sinus rhythm, as described in the US label of Betapace and Betapace AF

Recipient: Recipient not specified; Population: Patients described in the indications section of the label: patients with documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia, and patients with highly symptomatic atrial fibrillation or flutter who are currently in sinus rhythm. The passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Betapace and Betapace AF (sotalol hydrochloride tablets, Legacy Pharma USA, Inc., application NDA019865; the version dated 2024-12-16 in openFDA) describes the medicine as an antiarrhythmic. It lists the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia, and the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) in patients with highly symptomatic atrial fibrillation or flutter who are currently in sinus rhythm. It states that the medicine has not been shown to enhance survival in patients with life-threatening ventricular arrhythmias.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label: patients with documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia, and patients with highly symptomatic atrial fibrillation or flutter who are currently in sinus rhythm. The passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also gives limitations of use for the atrial fibrillation indication (reserve for highly symptomatic patients); those are the label's statements and are not repeated as advice. Contraindications, other warnings, the label's pediatric statements and dosing were not recorded. The oral solution (Sotylize) and generic labels were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for Betapace and Betapace AF (sotalol hydrochloride tablets), Legacy Pharma USA, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id a6a7702f-36c9-45db-b640-453dc324baee (manufacturer Legacy Pharma USA, Inc., application NDA019865; one label for the two brands Betapace and Betapace AF), returned on 2026-11-18. The label text is dated 2024-12-16 (effective\_time). Other openFDA records of sotalol labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22a6a7702f-36c9-45db-b640-453dc324baee%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], indications statement. Retrieved 2026-11-18T21:55:11Z. Source state: Current. Version fingerprint: c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00.
     How it applies: Label passage quoted in the research quote table (LB-04).
  2. Supports: openFDA drug label record for Betapace and Betapace AF (sotalol hydrochloride tablets), Legacy Pharma USA, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id a6a7702f-36c9-45db-b640-453dc324baee (manufacturer Legacy Pharma USA, Inc., application NDA019865; one label for the two brands Betapace and Betapace AF), returned on 2026-11-18. The label text is dated 2024-12-16 (effective\_time). Other openFDA records of sotalol labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22a6a7702f-36c9-45db-b640-453dc324baee%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.1 Life-Threatening Ventricular Arrhythmias. Retrieved 2026-11-18T21:55:11Z. Source state: Current. Version fingerprint: c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00.
     How it applies: Label passage quoted in the research quote table (LB-05, LB-06).
  3. Supports: openFDA drug label record for Betapace and Betapace AF (sotalol hydrochloride tablets), Legacy Pharma USA, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id a6a7702f-36c9-45db-b640-453dc324baee (manufacturer Legacy Pharma USA, Inc., application NDA019865; one label for the two brands Betapace and Betapace AF), returned on 2026-11-18. The label text is dated 2024-12-16 (effective\_time). Other openFDA records of sotalol labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22a6a7702f-36c9-45db-b640-453dc324baee%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.2 Delay in Recurrence of Atrial Fibrillation/Atrial Flutter (AFIB/AFL). Retrieved 2026-11-18T21:55:11Z. Source state: Current. Version fingerprint: c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00.
     How it applies: Label passage quoted in the research quote table (LB-07, LB-08).
  4. Background: openFDA drug label record for Betapace and Betapace AF (sotalol hydrochloride tablets), Legacy Pharma USA, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id a6a7702f-36c9-45db-b640-453dc324baee (manufacturer Legacy Pharma USA, Inc., application NDA019865; one label for the two brands Betapace and Betapace AF), returned on 2026-11-18. The label text is dated 2024-12-16 (effective\_time). Other openFDA records of sotalol labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22a6a7702f-36c9-45db-b640-453dc324baee%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T21:55:11Z. Source state: Current. Version fingerprint: c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00.
     How it applies: Effective date of the label text read, 20241216.

## Connected pages

- Sotalol is an antiarrhythmic (FDA established pharmacologic class in RxClass): Antiarrhythmic drugs (`cardio:antiarrhythmic-drugs`)
- FDA label lists treatment of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia, as an indication: Ventricular tachycardia (`cardio:ventricular-tachycardia`) [a claim, not a settled fact; see claim `cardio:claim-fda-sotalol-label-indications` and its context]
- FDA label lists keeping normal sinus rhythm, by delaying the recurrence of atrial fibrillation or flutter, in people with highly symptomatic episodes who are in sinus rhythm as an indication: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`) [a claim, not a settled fact; see claim `cardio:claim-fda-sotalol-label-indications` and its context]
- FDA label lists keeping normal sinus rhythm, by delaying the recurrence of atrial fibrillation or flutter, in people with highly symptomatic episodes who are in sinus rhythm as an indication: Atrial flutter (`cardio:atrial-flutter`) [a claim, not a settled fact; see claim `cardio:claim-fda-sotalol-label-indications` and its context]
- The label says sotalol has beta-adrenoreceptor blocking properties (Vaughan Williams Class II); RxClass lists the mechanism class Adrenergic beta-Antagonists: Beta-blockers (drug class) (`cardio:beta-blockers`)
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: 61ddc3b488b89f12cb4c6a6bbdaf8a89a1be478df909dddf25fc477fbe61566f
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
